Schizophrenia Mental and Behavioural Disorders Schizophrenia
Conditions
Interventions
Four groups were randomly allocated to placebo or 1 g, 2 g or 4 g ethyl-EPA/day on a double blind basis. Treatment duration 12 weeks.
Sponsors
Laxdale Ltd (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent 2. Diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria 3. Minimum duration of 12 weeks from diagnosis 4. Maximum duration of 20 years from diagnosis 5. Maintained on same neuroleptic drug(s) for 12 weeks and on the same dose for 4 weeks 6. Total Positive and Negative Syndrome Scale (PANSS) score of 50 or more and a positive sub-scale PANSS score of 15 or more 7. Aged 18 - 65 of either sex 8. In-patient or out-patient
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed